https://drugnews.com.tw/articles/2026-07-11-fasedienol-cns.html Drugnews｜藥時事 zh-tw 2026-07-11T01:49:15.886Z 社恐神藥三期踩煞車：Fasedienol 不是輸在故事，而是輸在 CNS 新藥最難證明的一格 https://drugnews.com.tw/articles/2026-07-11-fasedienol-cns-en.html Drugnews｜藥時事 en 2026-07-11T01:49:00.000Z Fasedienol's Phase 3 Brake: The Story Did Not Fail. The CNS Evidence Bar Did Its Job. https://drugnews.com.tw/articles/2026-07-10-fda-nasp-en.html Drugnews｜藥時事 en 2026-07-10T01:49:00.000Z Sobi's NASP Received an FDA CRL: The Problem Was Manufacturing Credibility, Not Efficacy https://drugnews.com.tw/articles/2026-07-10-fda-nasp.html Drugnews｜藥時事 zh-tw 2026-07-10T01:49:00.000Z 痛風新藥被 FDA 打回票：NASP 沒輸在療效，而是卡在製造可信度